@EliLillyandCo@VicCaserta Eli Lilly wants a war on Retatrutide, but consumers will win it. Lawsuits won't buy market share—they just burn cash. At $1,000/pen, Lilly only captures 3% while 97% pays $50 elsewhere. Want to actually win? Drop the price to $100 and take the 97%.
@EliLillyandCo Eli Lilly wants a war on Retatrutide, but consumers will win it. Lawsuits won't buy market share—they just burn cash. At $1,000/pen, Lilly only captures 3% while 97% pays $50 elsewhere. Want to actually win? Drop the price to $100 and take the 97%.
@EliLillyandCo Eli Lilly wants a war on Retatrutide, but consumers will win it. Lawsuits won't buy market share—they just burn cash. At $1,000/pen, Lilly only captures 3% while 97% pays $50 elsewhere. Want to actually win? Drop the price to $100 and take the 97%.
Eli Lilly wants a war on Retatrutide, but consumers will win it. Lawsuits won't buy market share—they just burn cash. At $1,000/pen, Lilly only captures 3% while 97% pays $50 elsewhere. Want to actually win? Drop the price to $100 and take the 97%. @EliLillyandCo#retatrutide